Ask AI
Translating Discoveries in cSCC

CE / CME

Clinical Focus: Translating Discoveries Into Clinical Practice to Advance the Care of Patients With Cutaneous Squamous Cell Carcinoma

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: January 26, 2026

Expiration: July 25, 2026

Activity

Progress
1 2
Course Completed

References

  1. Wysong A, et al. Epidemiology and unmet needs in cSCC: A 2023 update. Dermatol Surg. 2023;49:4-11.
  2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: squamous cell skin cancer V1.2026). nccn.org. Accessed January 16, 2026.
  3. Stratigos AJ, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin. Eur J Cancer. 2023;183:254-282.
  4. Migden MR, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341-351.
  5. Hughes BGM, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study). Ann Oncol. 2021;32:1276-1285.
  6. Rischin D, et al. Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N Engl J Med. 2025;393:774-785.
  7. Claveau J, et al. Multidisciplinary management of cutaneous squamous cell carcinoma of the scalp. J Clin Med. 2020;9:1581.
  8. Vetter M, et al. Integrating geriatric care in clinical oncology practice. Healthbook TIMES Onco Hema. 2024;17:14-19.
  9. Rischin D, et al. Phase II study of cemiplimab in patients with advanced cSCC: Longer follow-up. J Clin Oncol. 2020;38(suppl 15):abstr 10018.
  10. Muñoz-Couselo I, et al. Updated results from KEYNOTE-629. Ann Oncol. 2024;35:184-192.
  11. Ruiz ES, et al. Efficacy and safety of cosibelimab in locally advanced and metastatic cSCC: A 2025 update. J Clin Oncol. 2025;43(suppl 16):abstr 9508.
  12. Coppola A, et al. Real-world effectiveness of PD-1 inhibitors in elderly patients with advanced cSCC. J Dermatol Treat. 2024;35:2294312.
  13. Varga A, et al. Tolerability and outcomes of immunotherapy in very old patients with skin cancer. Cancers (Basel). 2024;16:782.
  14. Gross ND, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387:1557-1568.
  15. Gross ND, et al. Neoadjuvant cemiplimab and surgery for stage II–IV cSCC: Follow-up and survival outcomes. J Clin Oncol. 2023;41(suppl 16):abstr 9503.
  16. Amatore F, et al. Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cSCC. J Clin Oncol. 2024;42(suppl 16):abstr 9591.
  17. Ladwa R. Neoadjuvant pembrolizumab in cutaneous squamous cell carcinoma: Responses with 4 preoperative doses. J Clin Oncol. 2024;42(suppl 16):abstr 9514.
  18. Divi V, et al. Neoadjuvant atezolizumab in surgically resectable advanced cutaneous squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2024;150:312-320.
  19. Bruekers SM, et al. Neoadjuvant ipilimumab and nivolumab in resectable cSCC: A randomized phase 2 trial (MATISSE). J Clin Oncol. 2025;43(suppl 16):abstr 9505.
  20. Schenker M, et al. KEYNOTE-630: Adjuvant pembrolizumab versus placebo in high-risk locally advanced cSCC. Ann Oncol. 2024;35(suppl 2):S1041.
  21. Koyfman SA, et al. Phase 3 trial (KEYNOTE-630) of adjuvant pembrolizumab versus placebo for high-risk cSCC. J Clin Oncol. 2025;43(suppl 17):abstr 6000.
  22. Schenker M, et al. Overall survival and final analysis of the KEYNOTE-630 trial. J Clin Oncol. 2025;43(suppl 17):abstr 6001.
  23. Reckling K, Miller A. Advances in immunotherapy for non-melanoma skin cancers: a 2025 update. J Clin Oncol. 2025;43(suppl 16):abstr 9501.
  24. Harrington KJ, Migden MR. The evolving landscape of adjuvant therapy in cutaneous squamous cell carcinoma. Lancet Oncol. 2025;26:e284-e295.
  25. Schneider BJ, et al. Management of immune-related adverse events: ASCO Guideline Update. J Clin Oncol. 2021;39:4073-4126.
  26. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Management of immunotherapy-related toxicities V1.2024. nccn.org. Accessed January 16, 2026.
  27. Miller A, et al. Bayesian synthesis of C-POST and KEYNOTE-630: Understanding the treatment effect in cSCC. Lancet Oncol. 2025;26:112-114.
  28. Patel SP, et al. Neoadjuvant-adjuvant pembrolizumab for resectable melanoma. N Engl J Med. 2023;388:813-823.
  29. Blank CU, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma (NADINA). N Engl J Med. 2024;391:1102-1113.
  30. Long GV, et al. Pathologic response as a surrogate for survival in patients with resectable cutaneous squamous cell carcinoma (cSCC) treated with neoadjuvant PD-1 blockade. Ann Oncol. 2023;34(suppl 2):S1038.
  31. Patel SP, et al. SWOG S1801: Three-year outcomes of neoadjuvant-adjuvant pembrolizumab vs adjuvant pembrolizumab for resectable stage III–IV melanoma. Presented at: ESMO Congress 2025; October 17–21, 2025; Berlin, Germany. Abstract 1601O.
  32. Lucas MW, Menzies AM, Dimitriadis P, et al. Two-year clinical update and first biomarker analyses of the phase 3 NADINA trial comparing neoadjuvant nivolumab plus ipilimumab vs adjuvant nivolumab in resectable stage III melanoma. Presented at: ESMO Congress 2025; October 17–25, 2025; Berlin, Germany. Abstract LBA57.
  33. Migden MR, et al. EMPOWER-CSCC-1: Final long-term analysis (groups 1–3) and primary analysis of fixed-dose treatment (group 6) in advanced cutaneous squamous cell carcinoma. Ann Oncol. 2022;33(suppl 7). Abstract 814P.
  34. Bratland A. KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma. J Clin Oncol. 2021;39(suppl):abstr 9546.
  35. Vasudevan SS. Current efficacy and safety and survival outcomes of cemiplimab in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis. J Invest Dermatol. 2025;145(10):2623-2626.e5.
  36. Suero-Abreu GA, Zanni MV, Neilan TG. Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2022;4:598-615.
  37. Grob JJ, et al. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). J Clin Oncol. 2020;38:2916-2925.
  38. Hughes BGM, et al. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J Am Acad Dermatol. 2024;91(5):856-866.
  39. Demaria S, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021;9:e002038.